Gossamer Bio reprices CCO stock options to $0.45

Gossamer Bio Chief Commercial Officer option repricing: Gossamer Bio, Inc. adjusted stock option awards held by Chief Commercial Officer Robert Paul Smith Jr.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Gossamer Bio Chief Commercial Officer option repricing: Gossamer Bio, Inc. adjusted stock option awards held by Chief Commercial Officer Robert Paul Smith Jr. Effective as of March 19, 2026, the company approved a one-time repricing of certain outstanding options, lowering their exercise price to $0.45 per share while keeping vesting schedules and terms unchanged. Two existing option grants for 562,500 and 572,000 shares of common stock were disposed of back to the issuer at prior exercise prices of $2.88 and $1.13 per share, and replacement options for the same respective share amounts were granted at the new $0.45 exercise price under the 2019 Incentive Award Plan.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Smith Robert Paul JR

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Disposition	Stock Option (Right to Buy)	562,500	$0.00	$0.00
Disposition	Stock Option (Right to Buy)	572,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	562,500	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	572,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 1,134,500 contracts (Direct)

Footnotes (2)

F1. Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.
F2. This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Gossamer Bio (GOSS) disclose in this Form 4 filing?

Gossamer Bio reported that Chief Commercial Officer Robert Paul Smith Jr. participated in a one-time stock option repricing on March 19, 2026. Certain existing options were surrendered to the company and replaced with new options at a lower exercise price of $0.45 per share.

How many Gossamer Bio options were repriced for the Chief Commercial Officer?

Two option grants were repriced: one covering 562,500 shares and another covering 572,000 shares of Gossamer Bio common stock. Both original grants were disposed of to the issuer and replaced with new options for the same share amounts at a reduced $0.45 exercise price.

What were the original and new exercise prices for GOSS stock options?

The filing shows original exercise prices of $2.88 and $1.13 per share for the affected Gossamer Bio options. After the one-time repricing effective March 19, 2026, both grants were reset to a lower exercise price of $0.45 per share under the 2019 Incentive Award Plan.

Did the vesting terms change for the repriced Gossamer Bio options?

The filing states that only the exercise price changed in this option repricing. All other terms and conditions, including vesting and the remaining term of the repriced options, continue in full force according to the original award agreements and the 2019 Incentive Award Plan.

Were these GOSS option transactions open-market buys or sells?

No. The Form 4 classifies the dispositions as returns of options to the issuer and the acquisitions as grants or awards. The transaction codes show issuer disposition and grant activity, not open-market purchases or sales of Gossamer Bio common stock.

What plan governs the repriced Gossamer Bio stock options?

All affected options were granted under Gossamer Bio’s 2019 Incentive Award Plan. The Form 4 notes that the repricing simply reduced the exercise price to $0.45 per share, while the plan-based terms, including vesting schedules, remain unchanged for the Chief Commercial Officer’s awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/20/2026 - 04:19 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Robert Paul JR

(Last)

(First)

(Middle)

3115 MERRYFIELD ROW, SUITE 120

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Gossamer Bio, Inc. [ GOSS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.88	03/19/2026		D⁽¹⁾			562,500	⁽²⁾	01/01/2036	Common Stock	562,500	⁽¹⁾	0	D
Stock Option (Right to Buy)	$1.13	03/19/2026		D⁽¹⁾			572,000	⁽²⁾	03/03/2035	Common Stock	572,000	⁽¹⁾	0	D
Stock Option (Right to Buy)	$0.45	03/19/2026		A⁽¹⁾		562,500		⁽²⁾	01/01/2036	Common Stock	562,500	⁽¹⁾	562,500	D
Stock Option (Right to Buy)	$0.45	03/19/2026		A⁽¹⁾		572,000		⁽²⁾	03/03/2035	Common Stock	572,000	⁽¹⁾	572,000	D

Explanation of Responses:

1. Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

2. This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Remarks:

	/s/ Jeff Boerneke, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR